Type2 Diabetes MellitusNCT03901248
Study of Association of Salivary Adipokines With Prediabetes and Type 2 Diabetes Mellitus
An observational study of Type2 Diabetes Mellitus, run by India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals.
Trial summary
India has more than 65 million adults with Type 2 Diabetes Mellitus (T2DM) and also has a large number with subclinical stages of glycaemia including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Read more about this study
- Who is it for?
- Ages 35 years and olderHealthy volunteers can take part
- Conditions the study is for
- Type2 Diabetes Mellitus
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- Jul 2015to Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Normoglycemic, prediabetic and newly diagnosed Type 2 diabetic participants
Who may be able to join
- Particpants both men and women will be selected for screening using risk factors for diabetes such as age ≥ 35 years, family history of diabetes, previous history of hypertension, sedentary life-style, gestational diabetes, previous history of borderline diabetes, waist circumference ≥ 90 cm males \& ≥ 80cm in females, Body Mass Index (BMI) ≥ 23kg/m2. 2hr plasma glucose will be done for those subjects who have 3 or more risk factors.
- Arm 1: 2hr plasma glucose after 75gm of Glucose - < 140 mg/dl
- Arm 2: 2hr plasma glucose after 75gm of Glucose - ≥ 140 mg/dl to < 199 mg/dl
- Arm 3: 2hr plasma glucose after 75gm of Glucose - ≥ 200 mg/dl
- Have given written informed consent to participate in this study in accordance with local regulations
Who cannot join
- Smokers for over a period of 6 months (1 or more cigarettes per day).
- Beetle nut chewer over a period of 3 months.
- Patients with bleeding disorders
- Patients who require antibiotic prophylaxis prior to dental treatment.
- History of antibiotic therapy within 3 months prior to the study
- Patients with uncontrolled systemic disease
- Partipants who is not willing to participate in the study
- Individuals who are cognitively impaired and/or who are unable to give informed consent.
About this study
India has more than 65 million adults with Type 2 Diabetes Mellitus (T2DM) and also has a large number with subclinical stages of glycaemia including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). At present people with high risk of diabetes are identified by blood test such as Oral glucose tolerance Test and/or glycosylated haemoglobin A1c (HbA1c). Dysregulated actions of adipokines have major roles in development of metabolic diseases such as diabetes. Adipokines influence systemic insulin resistance and also regulate inflammatory process and/or are likely to have major pathological role in the development of diabetes. It is also likely that these abnormalities occur even in sub clinical stages of T2DM which when identified would provide an early opportunity to institute early intervention using life style changes which are proven to be effective in all ethnic groups.The measurements of adipokines such as adiponectin, apelin, visfatin and vaspin which have inter related regulatory roles, in saliva if found to be sensitive would provide a non-invasive, simple method of assessing persons with high risk of T2DM.
Read the detailed description
This study is conducted in a tertiary care hospital, Dr.A.Ramachandran's Diabetes Hospitals, Chennai. The persons with no history of diabetes, seeking a screening for diabetes will be invited to participate in the study and after signing the informed consent form they will be assessed by the risk score. The patients who fulfill the inclusion criteria will be enrolled in this study and additional tests will be done. We will also invite the patient's spouse, relatives or friends who are willing to participant in this study.
Preliminary screening: The team comprises of one research associate (dentist), one research associate, two laboratory technicians and one lab assistant. The measurements will be assessed by the same members of the team throughout screening, to eliminate potential inter-observer variation. Participants aged ≥35 years who visit the clinic will be invited to undergo a preliminary screening. Weight and height are measured with the participants wearing light clothes without shoes. BMI is calculated (kg/m2). Waist circumference is measured midway between the lower rib margin and the iliac crest. Blood pressure is measured using a standard mercury sphygmomanometer after a 5-minute rest. An average of the two readings is used for the analysis. Previous history of hypertension, borderline diabetes and gestational diabetes will be ascertained. Family history of diabetes, heart disease, stroke and sedentary life style are recorded in a structured questionnaire. If the participant has 2 or more risk factors they will be tested for fasting and 2h plasma glucose after 75gm of Oral Glucose (Accu check performa, Roche Diagnostics).
Next day participants will be categorized based on the inclusion and exclusion criteria as Normoglycemic, Pre diabetic (IFG/IGT) and newly diagnosed Type 2 diabetic patients. The selected participants will undergo dental examination to check for periodontitis. Then salivary and fasting serum sample is obtained from all the individuals for estimation of biomarkers (adiponectin, apelin, visfatin and vaspin). HbA1c, Lipid profile and Gamma-glutamyl transferase (GGT) is analysed in fasting serum.
Approximately 10 ml blood is collected in a serum tube. Blood sample separation is performed at the central investigational laboratory. Blood samples are separated, aliquoted, refrigerated and immediately stored at -70˚C for biomarker analysis. HbA1c is measured by immunoturbidometry (tina-quant II; roche diagnostics corporation, germany); a procedure certified by the national glycohemoglobin standardization programme. The fasting serum lipid profile (total cholesterol, triglycerides and high density lipoprotein, cholesterol) and GGT is estimated using standard enzymatic methods. Biochemical assays are performed on a Cobas Integra 450 plus (Roche, Germany) autoanalyzer using reagents from Roche diagnostics, with appropriate quality control methods (Roche diagnostics reference serum).
Unstimulated salivary samples will be collected in a sample collection tube. Participant will be asked to refrain from eating or drinking for about two hours prior to saliva collection; it is done around 8am - 10am. Subjects will be asked to rinse their mouth with drinking water and then to expectorate whole saliva in a collection tube. The saliva is then centrifuged at 9300g at 40 C for about 10 minutes and then stored at -70 degree C, until further use.
Saliva and plasma will be thawed at room temperature for biomarkers measurement by enzyme-linked immunosorbent assay (ELISA). A commercial ELISA kit for human biomarkers for serum and saliva is used and the assay is conducted according to the manufacturer's instructions. Each sample of saliva and plasma from the same patient will be analysed in the same experimental set. Plasma samples require dilution. Saliva samples will be analyzed without dilution.
Reports will be dispatched from the central laboratory to the participants by courier. Participants with newly diagnosed diabetes or uncontrolled diabetes will be referred to a diabetologist for treatment and followed up for two year. Individuals with prediabetes will be advised to improve physical activity and dietary habits and followed up for two year. Participants with periodontitis will be referred to a dental surgeon and followed up for two year.
During visit 4 \& 6 the participant's weight, waist circumference, BMI, blood pressure will be measured and laboratory investigations like Fasting and 2hr postprandial blood glucose, HbA1c and Lipid profile. At Visit 6 the participant's saliva and serum samples are collected for adipokines measurement.
- Conditions
- Type2 Diabetes Mellitus
- Being tested
- No Intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No InterventionOther
Observational study
| Study group | Role | What they receive |
|---|---|---|
| Normoglycemia | Participant with normal blood glucose level with No Intervention Receives: Other: No Intervention | |
| Impaired Glucose Tolerance | Participants with Impaired Glucose Tolerance blood glucose level with No Intervention Receives: Other: No Intervention | |
| Type 2 Diabetes | Newly diagnosed type 2 diabetes patients with No Intervention Receives: Other: No Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages
Levels of adiponectin, visfatin, vaspin and apelin in prediabetes and diabetes
Measured: Baseline and 2 years
Secondary outcomes (7)
Change in BMI
BMI changes
Measured: Baseline and 2 years
Change in Blood Pressure
Blood Pressure changes
Measured: Baseline and 2 years
Change in fasting blood glucose
Blood pressure Changes
Measured: Baseline and 2 years
Change in postprandial blood glucose
Postprandial blood glucose changes
Measured: Baseline and 2 years
Comparative assessment of the sensitivity of the assays of the biomarkers in saliva and serum
The sensitivity of biomarkers in saliva and serum
Measured: Baseline and 2 years
Levels of these biomarkers in the presence of periodontitis
Relationship of Biomarkers in the presence of periodontitis
Measured: Baseline and 2 years
Change in HbA1c
HbA1c changes
Measured: Baseline and 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2019
- Study startJul 2015
- Primary completionSep 2019
- Study completionDec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type2 Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dr.Ramachandran Ambady, MD,PhD,DSc, Study chair, President, India Diabetes Research Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03901248
- Sponsor's protocol ID
- IDRFARH005
- Status last verified
- Jan 2020
- First submitted
- 4 Jun 2018
- Last updated
- 10 Jan 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Association of Salivary Adipokines With Prediabetes and Type 2 Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT03901248
- Acronym / sponsor ID
- IDRFARH005
- Conditions
- Type2 Diabetes Mellitus
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes HospitalsUniversity, hospital or other
- Study start
- Jul 2015 (actual)
- Primary completion
- Sep 2019 (actual)
- Study completion
- Dec 2019 (actual)
- First posted
- 3 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
India has more than 65 million adults with Type 2 Diabetes Mellitus (T2DM) and also has a large number with subclinical stages of glycaemia including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). At present people with high risk of diabetes are identified by blood test such as Oral glucose tolerance Test and/or glycosylated haemoglobin A1c (HbA1c). Dysregulated actions of adipokines have major roles in development of metabolic diseases such as diabetes. Adipokines influence systemic insulin resistance and also regulate inflammatory process and/or are likely to have major pathological role in the development of diabetes. It is also likely that these abnormalities occur even in sub clinical stages of T2DM which when identified would provide an early opportunity to institute early intervention using life style changes which are proven to be effective in all ethnic groups.The measurements of adipokines such as adiponectin, apelin, visfatin and vaspin which have inter related regulatory roles, in saliva if found to be sensitive would provide a non-invasive, simple method of assessing persons with high risk of T2DM.
Detailed description
This study is conducted in a tertiary care hospital, Dr.A.Ramachandran's Diabetes Hospitals, Chennai. The persons with no history of diabetes, seeking a screening for diabetes will be invited to participate in the study and after signing the informed consent form they will be assessed by the risk score. The patients who fulfill the inclusion criteria will be enrolled in this study and additional tests will be done. We will also invite the patient's spouse, relatives or friends who are willing to participant in this study.
Preliminary screening: The team comprises of one research associate (dentist), one research associate, two laboratory technicians and one lab assistant. The measurements will be assessed by the same members of the team throughout screening, to eliminate potential inter-observer variation. Participants aged ≥35 years who visit the clinic will be invited to undergo a preliminary screening. Weight and height are measured with the participants wearing light clothes without shoes. BMI is calculated (kg/m2). Waist circumference is measured midway between the lower rib margin and the iliac crest. Blood pressure is measured using a standard mercury sphygmomanometer after a 5-minute rest. An average of the two readings is used for the analysis. Previous history of hypertension, borderline diabetes and gestational diabetes will be ascertained. Family history of diabetes, heart disease, stroke and sedentary life style are recorded in a structured questionnaire. If the participant has 2 or more risk factors they will be tested for fasting and 2h plasma glucose after 75gm of Oral Glucose (Accu check performa, Roche Diagnostics).
Next day participants will be categorized based on the inclusion and exclusion criteria as Normoglycemic, Pre diabetic (IFG/IGT) and newly diagnosed Type 2 diabetic patients. The selected participants will undergo dental examination to check for periodontitis. Then salivary and fasting serum sample is obtained from all the individuals for estimation of biomarkers (adiponectin, apelin, visfatin and vaspin). HbA1c, Lipid profile and Gamma-glutamyl transferase (GGT) is analysed in fasting serum.
Approximately 10 ml blood is collected in a serum tube. Blood sample separation is performed at the central investigational laboratory. Blood samples are separated, aliquoted, refrigerated and immediately stored at -70˚C for biomarker analysis. HbA1c is measured by immunoturbidometry (tina-quant II; roche diagnostics corporation, germany); a procedure certified by the national glycohemoglobin standardization programme. The fasting serum lipid profile (total cholesterol, triglycerides and high density lipoprotein, cholesterol) and GGT is estimated using standard enzymatic methods. Biochemical assays are performed on a Cobas Integra 450 plus (Roche, Germany) autoanalyzer using reagents from Roche diagnostics, with appropriate quality control methods (Roche diagnostics reference serum).
Unstimulated salivary samples will be collected in a sample collection tube. Participant will be asked to refrain from eating or drinking for about two hours prior to saliva collection; it is done around 8am - 10am. Subjects will be asked to rinse their mouth with drinking water and then to expectorate whole saliva in a collection tube. The saliva is then centrifuged at 9300g at 40 C for about 10 minutes and then stored at -70 degree C, until further use.
Saliva and plasma will be thawed at room temperature for biomarkers measurement by enzyme-linked immunosorbent assay (ELISA). A commercial ELISA kit for human biomarkers for serum and saliva is used and the assay is conducted according to the manufacturer's instructions. Each sample of saliva and plasma from the same patient will be analysed in the same experimental set. Plasma samples require dilution. Saliva samples will be analyzed without dilution.
Reports will be dispatched from the central laboratory to the participants by courier. Participants with newly diagnosed diabetes or uncontrolled diabetes will be referred to a diabetologist for treatment and followed up for two year. Individuals with prediabetes will be advised to improve physical activity and dietary habits and followed up for two year. Participants with periodontitis will be referred to a dental surgeon and followed up for two year.
During visit 4 \& 6 the participant's weight, waist circumference, BMI, blood pressure will be measured and laboratory investigations like Fasting and 2hr postprandial blood glucose, HbA1c and Lipid profile. At Visit 6 the participant's saliva and serum samples are collected for adipokines measurement.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Normoglycemia | – | Other: No InterventionParticipant with normal blood glucose level with No Intervention |
| Impaired Glucose Tolerance | – | Other: No InterventionParticipants with Impaired Glucose Tolerance blood glucose level with No Intervention |
| Type 2 Diabetes | – | Other: No InterventionNewly diagnosed type 2 diabetes patients with No Intervention |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Normoglycemic, prediabetic and newly diagnosed Type 2 diabetic participants
Key inclusion criteria (5 listed)
- Particpants both men and women will be selected for screening using risk factors for diabetes such as age ≥ 35 years, family history of diabetes, previous history of hypertension, sedentary life-style, gestational diabetes, previous history of borderline diabetes, waist circumference ≥ 90 cm males \& ≥ 80cm in females, Body Mass Index (BMI) ≥ 23kg/m2. 2hr plasma glucose will be done for those subjects who have 3 or more risk factors.
- Arm 1: 2hr plasma glucose after 75gm of Glucose - < 140 mg/dl
- Arm 2: 2hr plasma glucose after 75gm of Glucose - ≥ 140 mg/dl to < 199 mg/dl
- Arm 3: 2hr plasma glucose after 75gm of Glucose - ≥ 200 mg/dl
- Have given written informed consent to participate in this study in accordance with local regulations
Key exclusion criteria (8 listed)
- Smokers for over a period of 6 months (1 or more cigarettes per day).
- Beetle nut chewer over a period of 3 months.
- Patients with bleeding disorders
- Patients who require antibiotic prophylaxis prior to dental treatment.
- History of antibiotic therapy within 3 months prior to the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No InterventionObservational study | Other | Impaired Glucose Tolerance, Normoglycemia, Type 2 Diabetes |
Primary outcome
Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages
Time frame: Baseline and 2 years
Levels of adiponectin, visfatin, vaspin and apelin in prediabetes and diabetes
7 secondary outcomes
Change in BMI
Time frame: Baseline and 2 years
Change in Blood Pressure
Time frame: Baseline and 2 years
Change in fasting blood glucose
Time frame: Baseline and 2 years
Change in postprandial blood glucose
Time frame: Baseline and 2 years
Comparative assessment of the sensitivity of the assays of the biomarkers in saliva and serum
Time frame: Baseline and 2 years
Levels of these biomarkers in the presence of periodontitis
Time frame: Baseline and 2 years
Change in HbA1c
Time frame: Baseline and 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Type2 Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr.Ramachandran Ambady, MD,PhD,DSc study chair
President, India Diabetes Research Foundation
Questions about this trial
What is this clinical trial studying?
An observational study of Type2 Diabetes Mellitus, run by India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages (time frame: Baseline and 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2020.